Pediatric Hematology and Oncology Research

The Division of Pediatric Hematology and Oncology is nationally distinguished for its design and conduct of NIH-funded multicenter clinical trials involving childhood cancer, sickle cell disease, and hemorrhagic disorders.

Laboratory Research

Faculty are conducting molecular and cellular biology experiments in cancer and blood disease. Laboratory research efforts are both basic and translational studies that help to bridge the lab and clinical venues. Research is carried out in laboratories at UT Southwestern, the Children’s Medical Center Research Institute at UT Southwestern, and Children's Healthâ„ .

Active areas of basic research include:

  • Using fruit fly and zebrafish models to understand the genetic defects causing rhabdomyosarcoma, Ewing sarcoma and malignant germ cell tumor
  • Using complementary pre-clinical models to dissect the key “vulnerabilities” in rhabdomyosarcoma
  • Understanding the molecular machinery by which normal cells can undergo “senescence” as a tumor suppressor mechanism in the presence of a cancer-causing oncogene
  • Identifying novel proteins that can be “targeted” as novel therapies in childhood cancer
  • Understanding how certain cancer-causing mutations influence the metabolism in childhood brain tumors and certain types of sarcoma
  • Uncovering how hematopoietic and embryonic stem cells are controlled and how these control mechanisms can go awry in cancer and blood disease
  • Elucidating the molecular machinery that guides erythrocyte development
  • Using novel model systems to elucidate the host and bacterial factors that cause invasive bacterial and fungal infections

Clinical Research

Physicians at the Gill Center are engaged in a wide range of clinical research efforts spanning the cancer and blood disease programs. Clinical research efforts are supported by robust infrastructure provided by the Clinical Research Office (CRO) within the Gill Center and the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern, the only NCI-designated Comprehensive Cancer Center in North Texas. At any point, 75 to 100 oncology trials and 20 to 30 hematology trials are open for enrollment for Gill Center patients.

Active areas of clinical research include:

  • Prospective clinical trials for children with cancer, conducted under the umbrella of the NCI-sponsored Children’s Oncology Group
  • Prospective, early-phase clinical trials for children with hematological malignancies, conducted as part of the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium
  • Prospective therapeutic trials for children with sickle cell disease, iron deficiency anemia and hemophilia
  • Investigator-initiated and industry-sponsored therapeutic studies of children with cancer and blood disease
  • Retrospective research studies investigating molecular and clinical factors influencing late effects in childhood cancer survivors
  • Prospective and retrospective studies assessing a variety of quality measures of children with chronic hematology disorders

Research Funding

Clinical and laboratory research efforts are funded by a wide variety of national, regional and local organizations such as the National Cancer Institute; the National Heart, Lung, and Blood Institute; National Eye Institute; Cancer Research and Protection Institute of Texas; American Cancer Society; St. Baldrick’s Foundation; Children’s Cancer Fund of Dallas; Children’s Medical Center Foundation; Wipe-Out Kids’ Cancer; and Hyundai Hope on Wheels Foundation.